Trial Profile

A prospective phase 3 study of CNM-Au8 in amyotrophic lateral sclerosis patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CNM Au8 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Therapeutic Use
Acronyms RESTORE-ALS

Most Recent Events

10 Dec 2024 According to a Clene Nanomedicine media release, Clene plans to commence the confirmatory Phase 3 RESTORE-ALS trial with participant enrollment beginning prior to the submission of the NDA.
13 Nov 2024 According to a Clene Nanomedicine media release, company presented the design for RESTORE-ALS at the 2024 Annual Northeast Amyotrophic Lateral Sclerosis Consortium.
21 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com